On May 9, 2023 Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, reported that preclinical data for its oncogenic driver program targeting KRAS G12D, AFNT–212, will be presented at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 26th Annual Meeting in Los Angeles, California (Press release, Affini-T Therapeutics, MAY 9, 2023, View Source [SID1234631315]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our mission is to address the significant unmet needs of patients with hard-to-treat solid tumors by advancing precision immunotherapies that target oncogenic driver mutations," said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. "We believe gene editing is an important tool in the development of cell therapies as it allows for precise and targeted modifications within cells, aimed to improve safety and activity of these therapies. We look forward to presenting encouraging preclinical data for our gene-edited KRAS G12D-targeting TCR-T cell therapy, AFNT-212, at ASGCT (Free ASGCT Whitepaper) this year."
Poster presentation details are as follows:
Abstract: #1691, May 19, 12:00-2:00 pm PT: Novel CRISPR-Associated Gene Editing Systems Enable Efficient and Specific TRAC/TRBC Knockout Triggering Robust Expression and Sensitivity of a T Cell Receptor Specific for Mutant KRAS G12D – Presenting Author: Ankit Gupta, Ph.D., Director of Gene Editing, Affini-T Therapeutics